GlassScriptPhysician profile
Drue Deangelo
NPI 1366030363
$7,267.90
in general payments reported to CMS, 2019-2025
32 companies · $2,497 in 2025
The $2,497 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $141 · 2023: $2,489 · 2024: $2,141 · 2025: $2,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,126.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,298.26 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $769.88 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $711.35 | 2022-2025 | |
| Amgen INC. | $497.12 | 2023-2025 | Repatha, Prolia, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $461.47 | 2023-2025 | Xifaxan, Trulance |
| Abbvie INC. | $446.74 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.32 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $341.61 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $245.28 | 2023 | Arexvy, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $224.53 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $189.57 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $155.94 | 2024-2025 | Korlym |
| Shield Therapeutics INC | $148.43 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $148.00 | 2024-2025 | |
| Heartflow, INC. | $144.75 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $140.72 | 2024-2025 | Nexletol |
| Astellas Pharma US INC | $140.39 | 2024-2025 | Veozah |
| Pfizer INC. | $126.15 | 2023-2025 | |
| Aerin Medical INC. | $117.27 | 2023 | |
| Stryker Corporation | $107.58 | 2025 | Omnicurve, Optablate, Mild Device Kit |
| Lundbeck LLC | $85.58 | 2023-2025 | Rexulti |
| Cvrx, INC. | $72.61 | 2024 | Barostim Neo System |
| Alkermes, INC. | $47.39 | 2025 | Vivitrol |
| Janssen Pharmaceuticals, INC | $36.37 | 2023 | Spravato |
| Nestle Healthcare Nutrition INC. | $36.07 | 2023 | |
| Saluda Medical Americas, INC. | $30.06 | 2025 | Evoke |
| Halozyme INC | $29.91 | 2023 | |
| Cleerly, INC. | $27.70 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Dexcom, INC. | $19.51 | 2024 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $17.34 | 2023 | Edarbi |
| Merck Sharp & Dohme LLC | $15.91 | 2025 | Capvaxive, Gardasil 9 |
| Currax Pharmaceuticals LLC | $15.09 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drue Deangelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.